Ratings Guangdong Hybribio Biotech Co.,Ltd.

Equities

300639

CNE100002N51

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-12 EDT			5-day change	1st Jan Change
6.27 ^CNY	-3.69%		+0.16%	-32.87%

04-26	Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-24	Guangdong Hybribio Biotech Co.,Ltd. Proposes Final Dividend for the Year 2023	CI

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The group's high margin levels account for strong profits.
The company's share price in relation to its net book value makes it look relatively cheap.
Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
GUANGDONG HYBRIBIO BIOTECH CO.,LTD.	-32.87%	578M		-
BIOMÉRIEUX	-3.58%	12.64B		B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-1.48%	8.46B		B-
DIASORIN S.P.A.	+8.70%	5.66B		B
LANTHEUS HOLDINGS, INC.	+24.26%	5.27B		C
AUTOBIO DIAGNOSTICS CO., LTD.	-4.58%	4.49B		C
10X GENOMICS, INC.	-52.41%	3.11B		D+
ANDON HEALTH CO., LTD.	+16.25%	2.87B	-	-
MYRIAD GENETICS, INC.	+30.69%	2.31B		C
GUANGZHOU WONDFO BIOTECH CO.,LTD	-4.08%	1.89B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes